S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
AI Stock Caught Trading Under Secret Name (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
AI Stock Caught Trading Under Secret Name (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
AI Stock Caught Trading Under Secret Name (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
AI Stock Caught Trading Under Secret Name (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app

Zoetis (ZTS) Stock Price, News & Analysis

$197.32
+1.57 (+0.80%)
(As of 02/9/2024 08:57 PM ET)
Today's Range
$195.59
$198.22
50-Day Range
$179.65
$200.09
52-Week Range
$151.03
$201.92
Volume
2.23 million shs
Average Volume
1.88 million shs
Market Capitalization
$90.59 billion
P/E Ratio
40.11
Dividend Yield
0.88%
Price Target
$223.78

Zoetis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
13.4% Upside
$223.78 Price Target
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.86mentions of Zoetis in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$3.14 M Sold Last Quarter
Proj. Earnings Growth
10.17%
From $5.41 to $5.96 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.74 out of 5 stars

Medical Sector

48th out of 922 stocks

Pharmaceutical Preparations Industry

14th out of 424 stocks


ZTS stock logo

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

ZTS Stock News Headlines

Zoetis (ZTS) Set to Announce Quarterly Earnings on Tuesday
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
PROOF: New One Ticker (Weekly) Payouts
A multimillionaire stock trader's research explains how focusing on just one ticker every week has generated payouts up to a rare 2,614% in under 11 days...AND he's brought proof to show the world!
Zoetis Declares Second Quarter 2024 Dividend
Brokerages Set Zoetis Inc. (NYSE:ZTS) Price Target at $223.78
PROOF: New One Ticker (Weekly) Payouts
A multimillionaire stock trader's research explains how focusing on just one ticker every week has generated payouts up to a rare 2,614% in under 11 days...AND he's brought proof to show the world!
Zoetis (NYSE:ZTS) Lowered to "Buy" at StockNews.com
Zoetis Inc - Ordinary Shares - Class A
Q4 2022 Zoetis Inc Earnings Call Transcript
Q1 2023 Zoetis Inc Earnings Call Transcript
Zoetis Inc Investor Day Transcript
Q2 2023 Zoetis Inc Earnings Call Transcript
Q3 2023 Zoetis Inc Earnings Call Transcript
Zoetis (ZTS) Reported Solid Quarterly Results
Zoetis Wins 2024 Catalyst Award
What 4 Analyst Ratings Have To Say About Zoetis
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Ex-Dividend for 12/1 Dividend
10/31/2023
Dividend Payable
12/01/2023
Ex-Dividend for 3/1 Dividend
1/18/2024
Today
2/12/2024
Next Earnings (Confirmed)
2/13/2024
Dividend Payable
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
98978V10
Employees
13,800
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$223.78
High Stock Price Target
$260.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+13.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$2.11 billion
Pretax Margin
34.38%

Debt

Sales & Book Value

Annual Sales
$8.08 billion
Cash Flow
$5.93 per share
Book Value
$9.45 per share

Miscellaneous

Free Float
458,563,000
Market Cap
$90.59 billion
Optionable
Optionable
Beta
0.88

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for February 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Zoetis was last updated on Monday, January 29, 2024 at 1:15 PM.

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. is a leading company in the animal health industry, with a strong presence both in the United States and internationally. This provides the company with a wide customer base and potential for growth.
  • The company offers a diverse range of animal health medicines, vaccines, and diagnostic products, catering to both livestock and companion animals. This diversified product portfolio helps mitigate risks associated with market fluctuations and provides multiple revenue streams.
  • Zoetis Inc. has a track record of innovation and research in the animal health sector. This positions the company well to capitalize on emerging trends and advancements in the industry, ensuring its products remain relevant and in demand.
  • The recent increase in Zoetis Inc.'s dividend payout is a positive sign for investors. A higher dividend payout indicates the company's confidence in its financial performance and its commitment to returning value to shareholders.
  • The stock price of Zoetis Inc. has shown positive performance, reaching a 1-year high of $201.92. This indicates potential capital appreciation for investors.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • The pharmaceutical industry, including the animal health sector, is subject to regulatory scrutiny and potential changes in government policies. This can impact the company's operations and profitability.
  • Zoetis Inc. faces competition from other players in the animal health industry. Increased competition may affect the company's market share and pricing power.
  • As a pharmaceutical company, Zoetis Inc. is exposed to risks associated with research and development. The success of new product development and regulatory approvals can impact the company's financial performance.
  • The company's debt-to-equity ratio of 1.29 indicates a relatively high level of debt. This increases the company's financial risk and may limit its ability to invest in growth opportunities or withstand economic downturns.
  • The beta of 0.85 suggests that Zoetis Inc.'s stock price is less volatile compared to the overall market. While this may be seen as a positive for some investors, it also means that the stock may have lower potential for significant price movements.














ZTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price target for 2024?

8 analysts have issued 12-month price targets for Zoetis' stock. Their ZTS share price targets range from $200.00 to $260.00. On average, they predict the company's stock price to reach $223.78 in the next year. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2024?

Zoetis' stock was trading at $197.37 on January 1st, 2024. Since then, ZTS shares have decreased by 0.0% and is now trading at $197.32.
View the best growth stocks for 2024 here
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ZTS earnings forecast
.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Tuesday, February 13th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings data on Tuesday, August, 8th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.31 by $0.10. The company earned $2.18 billion during the quarter, compared to analyst estimates of $2.16 billion. Zoetis had a net margin of 27.24% and a trailing twelve-month return on equity of 52.22%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the company earned $1.20 earnings per share.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Tuesday, February 6th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share on Tuesday, June 4th. This represents a $1.73 annualized dividend and a yield of 0.88%. The ex-dividend date is Thursday, April 18th.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.73 per share and currently has a dividend yield of 0.88%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 35.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 29.03% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?
Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Norges Bank (1.08%), Charles Schwab Investment Management Inc. (0.72%), Massachusetts Financial Services Co. MA (0.67%), Neuberger Berman Group LLC (0.63%), Clearbridge Investments LLC (0.63%) and Wells Fargo & Company MN (0.57%). Insiders that own company stock include Glenn David, Gregory Norden, Heidi C Chen, Kristin C Peck, Robert Edward Kelly, Robert J Polzer, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
This page (NYSE:ZTS) was last updated on 2/12/2024 by MarketBeat.com Staff

My Account -